BSX · News · 20260812N
Acquisition / Partnership / Divestiture
BOSTON SCIENTIFIC CORP · 2026-08-12 · Importance 58 · Surprise 42 · In source text
Boston Scientific is investing $1.5 billion in Marietta, Georgia-based MiRus to support its heart-valve replacement technology. MiRus is pursuing U.S. Food and Drug Administration approval for a heart valve using a superalloy. The transaction expands Boston Scientific’s strategic exposure to structural-heart technology and remains subject to the product’s FDA approval process.
Key facts
- Boston Scientific made a $1.5 billion investment in Marietta-based MiRus for its heart valve replacement technology. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | — | Boston Scientific made a $1.5 billion investment in Marietta-based MiRus for its heart valve replacement technology. |
| assets | positive | committed | — | Boston Scientific made a $1.5 billion investment in Marietta-based MiRus for its heart valve replacement technology. |